Which New Diagnostics for Tuberculosis, and When?

Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2012-05, Vol.205 (suppl_2), p.S191-S198
Hauptverfasser: Cobelens, Frank, van den Hof, Susan, Pai, Madhukar, Squire, S. Bertel, Ramsay, Andrew, Kimerling, Michael E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S198
container_issue suppl_2
container_start_page S191
container_title The Journal of infectious diseases
container_volume 205
creator Cobelens, Frank
van den Hof, Susan
Pai, Madhukar
Squire, S. Bertel
Ramsay, Andrew
Kimerling, Michael E.
description Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.
doi_str_mv 10.1093/infdis/jis188
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1018859689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23217124</jstor_id><sourcerecordid>23217124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</originalsourceid><addsrcrecordid>eNpF0L1PwzAQBXALgWgpjIygjAyE-uzYsSdUlU-pgqWoY5Q4NnWVJsWXCPHfE5QC0w3vpyfdI-Qc6A1Qzae-dqXH6cYjKHVAxiB4GksJ_JCMKWUsBqX1iJwgbiilCZfpMRkxlqQyBTkmsFp7s45e7Gd05_P3usHWG4xcE6JlV9hguqpBj9dRXpfRam3r21Ny5PIK7dn-Tsjbw_1y_hQvXh-f57NFbLhI2lgJ6gwrwbrCcZPmUiYFQMqBM-2EYYUuOLhcUVskos-1KoGWhgnrLCu54BNyNfTuQvPRWWyzrUdjqyqvbdNhBrR_WGipdE_jgZrQIAbrsl3w2zx89Sj7WSkbVsqGlXp_ua_uiq0t__TvLD24GMAG2yb855xBCizh39dWbY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018859689</pqid></control><display><type>article</type><title>Which New Diagnostics for Tuberculosis, and When?</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Cobelens, Frank ; van den Hof, Susan ; Pai, Madhukar ; Squire, S. Bertel ; Ramsay, Andrew ; Kimerling, Michael E.</creator><creatorcontrib>Cobelens, Frank ; van den Hof, Susan ; Pai, Madhukar ; Squire, S. Bertel ; Ramsay, Andrew ; Kimerling, Michael E. ; Evidence for Scale-up Group</creatorcontrib><description>Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jis188</identifier><identifier>PMID: 22476716</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Algorithms ; Antitubercular Agents - therapeutic use ; Bacteriological Techniques - economics ; Bacteriological Techniques - methods ; Bacteriological Techniques - trends ; Developing Countries ; Diagnostic methods ; Diagnostic tools ; Drug resistance ; Evaluation Studies as Topic ; Health outcomes ; Health Policy ; Humans ; Multidrug resistant tuberculosis ; Mycobacterium tuberculosis ; Recommendations ; Tuberculosis ; Tuberculosis - diagnosis ; Tuberculosis - drug therapy ; Tuberculosis control ; VIEWPOINT ARTICLE ; World Health Organization</subject><ispartof>The Journal of infectious diseases, 2012-05, Vol.205 (suppl_2), p.S191-S198</ispartof><rights>Copyright © 2012 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</citedby><cites>FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23217124$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23217124$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,782,786,805,27931,27932,58024,58257</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22476716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cobelens, Frank</creatorcontrib><creatorcontrib>van den Hof, Susan</creatorcontrib><creatorcontrib>Pai, Madhukar</creatorcontrib><creatorcontrib>Squire, S. Bertel</creatorcontrib><creatorcontrib>Ramsay, Andrew</creatorcontrib><creatorcontrib>Kimerling, Michael E.</creatorcontrib><creatorcontrib>Evidence for Scale-up Group</creatorcontrib><title>Which New Diagnostics for Tuberculosis, and When?</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.</description><subject>Algorithms</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Bacteriological Techniques - economics</subject><subject>Bacteriological Techniques - methods</subject><subject>Bacteriological Techniques - trends</subject><subject>Developing Countries</subject><subject>Diagnostic methods</subject><subject>Diagnostic tools</subject><subject>Drug resistance</subject><subject>Evaluation Studies as Topic</subject><subject>Health outcomes</subject><subject>Health Policy</subject><subject>Humans</subject><subject>Multidrug resistant tuberculosis</subject><subject>Mycobacterium tuberculosis</subject><subject>Recommendations</subject><subject>Tuberculosis</subject><subject>Tuberculosis - diagnosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis control</subject><subject>VIEWPOINT ARTICLE</subject><subject>World Health Organization</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0L1PwzAQBXALgWgpjIygjAyE-uzYsSdUlU-pgqWoY5Q4NnWVJsWXCPHfE5QC0w3vpyfdI-Qc6A1Qzae-dqXH6cYjKHVAxiB4GksJ_JCMKWUsBqX1iJwgbiilCZfpMRkxlqQyBTkmsFp7s45e7Gd05_P3usHWG4xcE6JlV9hguqpBj9dRXpfRam3r21Ny5PIK7dn-Tsjbw_1y_hQvXh-f57NFbLhI2lgJ6gwrwbrCcZPmUiYFQMqBM-2EYYUuOLhcUVskos-1KoGWhgnrLCu54BNyNfTuQvPRWWyzrUdjqyqvbdNhBrR_WGipdE_jgZrQIAbrsl3w2zx89Sj7WSkbVsqGlXp_ua_uiq0t__TvLD24GMAG2yb855xBCizh39dWbY4</recordid><startdate>20120515</startdate><enddate>20120515</enddate><creator>Cobelens, Frank</creator><creator>van den Hof, Susan</creator><creator>Pai, Madhukar</creator><creator>Squire, S. Bertel</creator><creator>Ramsay, Andrew</creator><creator>Kimerling, Michael E.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120515</creationdate><title>Which New Diagnostics for Tuberculosis, and When?</title><author>Cobelens, Frank ; van den Hof, Susan ; Pai, Madhukar ; Squire, S. Bertel ; Ramsay, Andrew ; Kimerling, Michael E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Algorithms</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Bacteriological Techniques - economics</topic><topic>Bacteriological Techniques - methods</topic><topic>Bacteriological Techniques - trends</topic><topic>Developing Countries</topic><topic>Diagnostic methods</topic><topic>Diagnostic tools</topic><topic>Drug resistance</topic><topic>Evaluation Studies as Topic</topic><topic>Health outcomes</topic><topic>Health Policy</topic><topic>Humans</topic><topic>Multidrug resistant tuberculosis</topic><topic>Mycobacterium tuberculosis</topic><topic>Recommendations</topic><topic>Tuberculosis</topic><topic>Tuberculosis - diagnosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis control</topic><topic>VIEWPOINT ARTICLE</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cobelens, Frank</creatorcontrib><creatorcontrib>van den Hof, Susan</creatorcontrib><creatorcontrib>Pai, Madhukar</creatorcontrib><creatorcontrib>Squire, S. Bertel</creatorcontrib><creatorcontrib>Ramsay, Andrew</creatorcontrib><creatorcontrib>Kimerling, Michael E.</creatorcontrib><creatorcontrib>Evidence for Scale-up Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cobelens, Frank</au><au>van den Hof, Susan</au><au>Pai, Madhukar</au><au>Squire, S. Bertel</au><au>Ramsay, Andrew</au><au>Kimerling, Michael E.</au><aucorp>Evidence for Scale-up Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which New Diagnostics for Tuberculosis, and When?</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2012-05-15</date><risdate>2012</risdate><volume>205</volume><issue>suppl_2</issue><spage>S191</spage><epage>S198</epage><pages>S191-S198</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>22476716</pmid><doi>10.1093/infdis/jis188</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 2012-05, Vol.205 (suppl_2), p.S191-S198
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_miscellaneous_1018859689
source MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects Algorithms
Antitubercular Agents - therapeutic use
Bacteriological Techniques - economics
Bacteriological Techniques - methods
Bacteriological Techniques - trends
Developing Countries
Diagnostic methods
Diagnostic tools
Drug resistance
Evaluation Studies as Topic
Health outcomes
Health Policy
Humans
Multidrug resistant tuberculosis
Mycobacterium tuberculosis
Recommendations
Tuberculosis
Tuberculosis - diagnosis
Tuberculosis - drug therapy
Tuberculosis control
VIEWPOINT ARTICLE
World Health Organization
title Which New Diagnostics for Tuberculosis, and When?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T20%3A44%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20New%20Diagnostics%20for%20Tuberculosis,%20and%20When?&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Cobelens,%20Frank&rft.aucorp=Evidence%20for%20Scale-up%20Group&rft.date=2012-05-15&rft.volume=205&rft.issue=suppl_2&rft.spage=S191&rft.epage=S198&rft.pages=S191-S198&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jis188&rft_dat=%3Cjstor_proqu%3E23217124%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1018859689&rft_id=info:pmid/22476716&rft_jstor_id=23217124&rfr_iscdi=true